- The two poster presentations will report -
- first combination data from the Phase 1/2a study with BI-1808 in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), as well as an update on monotherapy arm
- combination data from the Phase 1/2a study with BI-1206 in combination with KEYTRUDA for the treatment of patients with solid tumors
- Both BI-1808 and BI-1206 are first-in-class immunomodulatory agents with the potential to improve the efficacy of immune therapies and improve cancer outcomes
- BI-1808, an anti-TNFR2 antibody capable of targeting Tregs and modifying the tumor microenvironment, that could represent a new class of checkpoint inhibitors
- BI-1206, which blocks FcyRIIB, could overcome resistance to PD-1 inhibition
- Both posters will be presented at the
American Society for Clinical Oncology (ASCO 2024) Annual Meeting taking place at theMcCormick Place Convention Center inChicago, Illinois fromMay 31st to June 4th
“We are very pleased to be chosen to present data from our two lead candidates, BI-1808 (anti-TNFR2) and BI-1206 (anti-FccgRIIB) at ASCO 2024. Our research suggests that each of these first-in-class immunomodulatory agents have the potential to improve the efficacy of widely used immune therapies and improve cancer outcomes, said Martin Welschof, Chief Executive Officer of
Details of the abstracts to be presented:
Title: 19-B1-1808-01, a Phase 1/2a Clinical Trial of BI-1808, a Tumor Necrosis Factor Receptor 2 (TNFR2) Blocker/Depleter with or without Pembrolizumab
Abstract Number: 2641
Session: Developmental Therapeutics – Immunotherapy
Date:
Time:
Title: Phase 1/2a Clinical Trial of BI-1206, an Anti-CD32b (FCgammaRIIB) Antibody, in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Previously Treated with Anti-PD-1/PD-L1
Abstract Number: 2593
Session: Developmental Therapeutics – Immunotherapy
Date:
Time:
About
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow on the social media platform X: @BioInvent.
KEYTRUDA® is a registered trademark of
For further information, please contact:
Phone: +46 (0)46 286 85 50
Email: cecilia.hofvander@bioinvent.com
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.
© Modular Finance, source